−1.6393USD
−26.30 MUSD
895.48 KUSD
13.12 M
About Mainz Biomed N.V.
Sector
Industry
CEO
Guido Baechler
Website
Headquarters
Mainz
Founded
2021
ISIN
NL0015000LC2
FIGI
BBG012XZKGW7
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MYNZ is 0.9050 USD — it has increased by 0.11% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Mainz Biomed N.V. stocks are traded under the ticker MYNZ.
Mainz Biomed N.V. is going to release the next earnings report on Sep 4, 2024. Keep track of upcoming events with our Earnings Calendar.
MYNZ stock is 7.95% volatile and has beta coefficient of 1.53. Check out the list of the most volatile stocks — is Mainz Biomed N.V. there?
One year price forecast for Mainz Biomed N.V. has a max estimate of 2.0000 USD and a min estimate of 2.0000 USD.
MYNZ earnings for the last quarter are −0.27 USD per share, whereas the estimation was −0.32 USD resulting in a 14.74% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about Mainz Biomed N.V. earnings.
Mainz Biomed N.V. revenue for the last quarter amounts to 200.00 K USD despite the estimated figure of 253.33 K USD. In the next quarter revenue is expected to reach 318.00 K USD.
Yes, you can track Mainz Biomed N.V. financials in yearly and quarterly reports right on TradingView.
MYNZ stock has fallen by 9.50% compared to the previous week, the month change is a 9.50% fall, over the last year Mainz Biomed N.V. has showed a 81.53% decrease.
MYNZ net income for the last quarter is −5.18 M USD, while the quarter before that showed −6.30 M USD of net income which accounts for 17.72% change. Track more Mainz Biomed N.V. financial stats to get the full picture.
No, MYNZ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MYNZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Mainz Biomed N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Mainz Biomed N.V. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Mainz Biomed N.V. stock shows the sell signal. See more of Mainz Biomed N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Mainz Biomed N.V. future price: according to them, MYNZ price has a max estimate of 2.00 USD and a min estimate of 2.00 USD. Read a more detailed Mainz Biomed N.V. forecast: see what analysts think of Mainz Biomed N.V. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Mainz Biomed N.V. EBITDA is −25.48 M USD, and current EBITDA margin is −2.86 K%. See more stats in Mainz Biomed N.V. financial statements.